In Phase I and II studies, single agent neratinib therapy was well tolerated by patients, reducing the overall tumor burden and prolonging progression free survival (PFS) in patients with known ERBB2 or ERBB1/EGFR positive breast or lung tumors9,11. Here, EGFR is linked to neoplasm.